(CTRE) CareTrust REIT - Ratings and Ratios
Skilled Nursing, Senior Housing, Healthcare Properties
Dividends
| Dividend Yield | 3.57% |
| Yield on Cost 5y | 7.50% |
| Yield CAGR 5y | 3.78% |
| Payout Consistency | 91.1% |
| Payout Ratio | 98.7% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 21.7% |
| Value at Risk 5%th | 35.8% |
| Relative Tail Risk | 0.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.19 |
| Alpha | 24.86 |
| CAGR/Max DD | 1.29 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.282 |
| Beta | 0.233 |
| Beta Downside | 0.280 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.19% |
| Mean DD | 4.80% |
| Median DD | 3.04% |
Description: CTRE CareTrust REIT November 05, 2025
CareTrust REIT (CTRE) is a self-administered, publicly-traded REIT focused on owning, acquiring, developing, and leasing senior-housing and healthcare-related properties. Its revenue model relies on long-term leases to a diversified tenant base that includes local, regional, and national operators of senior housing, health-service providers, and other healthcare businesses.
Since its spin-off on June 1 2014, the REIT has expanded to 393 net-leased properties across 32 U.S. states and the United Kingdom, offering 35,719 operating beds/units. An additional 142 properties (13,944 beds) are held through related investments, plus a financing receivable tied to 46 properties (3,820 beds) in a single state, bringing total exposure to roughly 53,483 beds.
Key performance indicators from the most recent 10-K (June 30 2025) show an occupancy rate of ~94%, funds-from-operations (FFO) growth of 7.2% year-over-year, and a leverage ratio of 5.9× net debt to EBITDA, indicating moderate debt levels relative to cash flow generation.
Sector drivers that materially affect CTRE’s outlook include the U.S. aging-baby-boomer demographic (projected to add ~10 million adults aged 65+ by 2030), rising Medicare and Medicaid reimbursements that support operator profitability, and the sensitivity of REIT valuations to interest-rate movements-higher rates can compress cap rates and pressure share prices.
For a deeper quantitative dive into CTRE’s valuation metrics and peer comparison, the ValueRay platform offers a free, data-rich snapshot.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (261.4m TTM) > 0 and > 6% of Revenue (6% = 21.1m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -0.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 189.6% (prev 134.2%; Δ 55.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 348.3m > Net Income 261.4m (YES >=105%, WARN >=100%) |
| Net Debt (181.3m) to EBITDA (369.2m) ratio: 0.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (212.3m) change vs 12m ago 32.79% (target <= -2.0% for YES) |
| Gross Margin 97.43% (prev 94.27%; Δ 3.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.80% (prev 7.52%; Δ 1.28pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.69 (EBITDA TTM 369.2m / Interest Expense TTM 37.5m) >= 6 (WARN >= 3) |
Altman Z'' 0.49
| (A) 0.13 = (Total Current Assets 846.1m - Total Current Liabilities 177.9m) / Total Assets 5.09b |
| (B) -0.10 = Retained Earnings (Balance) -528.3m / Total Assets 5.09b |
| (C) 0.07 = EBIT TTM 287.9m / Avg Total Assets 4.00b |
| (D) -0.49 = Book Value of Equity -522.3m / Total Liabilities 1.07b |
| Total Rating: 0.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.97
| 1. Piotroski 5.50pt |
| 2. FCF Yield 3.88% |
| 3. FCF Margin 94.91% |
| 4. Debt/Equity 0.22 |
| 5. Debt/Ebitda 0.49 |
| 6. ROIC - WACC (= 0.49)% |
| 7. RoE 7.96% |
| 8. Rev. Trend 82.36% |
| 9. EPS Trend 55.71% |
What is the price of CTRE shares?
Over the past week, the price has changed by -3.74%, over one month by +0.25%, over three months by +7.16% and over the past year by +32.23%.
Is CTRE a buy, sell or hold?
- Strong Buy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CTRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.9 | 10% |
| Analysts Target Price | 39.9 | 10% |
| ValueRay Target Price | 46.5 | 28.2% |
CTRE Fundamental Data Overview December 06, 2025
P/E Trailing = 27.7647
P/E Forward = 12.9702
P/S = 19.6785
P/B = 2.1077
P/EG = 1.26
Beta = 0.8
Revenue TTM = 352.3m USD
EBIT TTM = 287.9m USD
EBITDA TTM = 369.2m USD
Long Term Debt = 893.8m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 893.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 181.3m USD (from netDebt column, last quarter)
Enterprise Value = 8.61b USD (8.43b + Debt 893.8m - CCE 712.5m)
Interest Coverage Ratio = 7.69 (Ebit TTM 287.9m / Interest Expense TTM 37.5m)
FCF Yield = 3.88% (FCF TTM 334.4m / Enterprise Value 8.61b)
FCF Margin = 94.91% (FCF TTM 334.4m / Revenue TTM 352.3m)
Net Margin = 74.19% (Net Income TTM 261.4m / Revenue TTM 352.3m)
Gross Margin = 97.43% ((Revenue TTM 352.3m - Cost of Revenue TTM 9.05m) / Revenue TTM)
Gross Margin QoQ = 99.58% (prev 96.45%)
Tobins Q-Ratio = 1.69 (Enterprise Value 8.61b / Total Assets 5.09b)
Interest Expense / Debt = 1.41% (Interest Expense 12.6m / Debt 893.8m)
Taxrate = 2.70% (2.08m / 77.0m)
NOPAT = 280.2m (EBIT 287.9m * (1 - 2.70%))
Current Ratio = 4.76 (Total Current Assets 846.1m / Total Current Liabilities 177.9m)
Debt / Equity = 0.22 (Debt 893.8m / totalStockholderEquity, last quarter 3.99b)
Debt / EBITDA = 0.49 (Net Debt 181.3m / EBITDA 369.2m)
Debt / FCF = 0.54 (Net Debt 181.3m / FCF TTM 334.4m)
Total Stockholder Equity = 3.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.14% (Net Income 261.4m / Total Assets 5.09b)
RoE = 7.96% (Net Income TTM 261.4m / Total Stockholder Equity 3.28b)
RoCE = 6.89% (EBIT 287.9m / Capital Employed (Equity 3.28b + L.T.Debt 893.8m))
RoIC = 6.83% (NOPAT 280.2m / Invested Capital 4.10b)
WACC = 6.34% (E(8.43b)/V(9.33b) * Re(6.87%) + D(893.8m)/V(9.33b) * Rd(1.41%) * (1-Tc(0.03)))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 32.08%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈282.9m ; Y1≈349.0m ; Y5≈595.5m
Fair Price DCF = 45.36 (DCF Value 10.13b / Shares Outstanding 223.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 55.71 | EPS CAGR: 16.02% | SUE: -1.03 | # QB: 0
Revenue Correlation: 82.36 | Revenue CAGR: 30.28% | SUE: 0.62 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.43 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=1.71 | Chg30d=-0.010 | Revisions Net=+1 | Growth EPS=-3.5% | Growth Revenue=+24.2%
Additional Sources for CTRE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle